WEBULL
WebtradeDownload

Novo Nordisk (CPSE:NOVO B) Could Be 67% Undervalued Following Sickle Cell And MASH Progress

Simply Wall St · 12h ago

Novo Nordisk (CPSE:NOVO B) has pushed its R&D story forward with two catalysts. Regulators are reviewing etavopivat for sickle cell disease, while new real world semaglutide data in MASH highlights broader cardiometabolic ambitions.

Novo Nordisk’s latest sickle cell and MASH headlines arrive after a mixed share price run, with a 30 day share price return of 8.79%, a year-to-date share price decline of 15.69%, and a 3-year total shareholder return down 56.30%. This suggests recent momentum is rebuilding from a much weaker long-term base.

Scan how Novo Nordisk’s R&D momentum in obesity and rare disease compares with peers by reviewing a curated set of 123 healthcare AI stocks targeting similar cardiometabolic and data driven therapies.

After a 56% three year total return decline and a cheaper P/E than peers, bulls see Novo Nordisk as mispriced GLP 1 and rare disease exposure. Bears point to competition, pipeline risk and governance change. Which case does the valuation lean toward?

Most Popular Narrative: 67% Undervalued

The narrative fair value of DKK851.04 sits far above Novo Nordisk’s last close of DKK278.45, according to Tokyo, an investor in the Simply Wall St Community who set out a detailed five year roadmap grounded in revenue, margin and discount rate assumptions.

Over the next 5 years I calculate with:

Revenue Growth p.a.: 14% (Currently at 12%), because of fab expansion

Profit Margin: 35% (same as current)

Future PE: 24 (currently at 18), because the 15 year average is 24

Interest rate: 4.74% (same as current)

Which leads to an FV of 850 DKK, which means NOVO trades at 52% below fair value (CV: 409 DKK, 11.04.25).

I calculated the interest rate of an investment at the current stock price of 409 DKK (11.04.25). At this value I get 13% annual return.

See why 105 investors see Novo Nordisk as 67% undervalued.

Result: Fair Value of DKK851.04 (UNDERVALUED)

Still, pricing pressure in obesity treatments and any setback in Novo Nordisk’s late stage pipeline could quickly weaken confidence in that undervalued story.

Find out about the key risks to this Novo Nordisk narrative.

Next Steps

Mixed sentiment runs through this Novo Nordisk story. Move quickly, pull up the data, and weigh both the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Novo Nordisk?

If Novo Nordisk has sharpened your focus on quality, do not stop here. Broaden your watchlist now or you risk missing the next compelling setup.